Keywords

• Thiamidol
• Export 1428450-95-6
• 1428450-95-6 Lowest Price

Quick Details

• ProName: Quality Manufacturer Supply 1428450-95...
• CasNo: 1428450-95-6
• Molecular Formula: C13H14N2O3S
• Application: Clinical studies have shown that Thiam...
• ProductionCapacity: Metric Ton/Day
• Purity: 99%
• LimitNum: 0 Metric Ton

Superiority

Quality Manufacturer Supply 1428450-95-6, Export Thiamidol with Lowest Price, accept customization.

Details

Thiamidol is a patented ingredient developed by Eucerin, known for its efficacy as a potent inhibitor of human tyrosinase, the enzyme responsible for melanin production.

Quality Manufacturer Supply 1428450-95-6, Export Thiamidol with Lowest Price

Inhibition of Tyrosinase:

Thiamidol is recognized as the most potent inhibitor of human tyrosinase among 50,000 tested compounds.

Tyrosinase is the enzyme responsible for converting tyrosine into melanin, the pigment responsible for skin color.

Clinical Studies:

Clinical studies have demonstrated the significant improvement of various types of hyperpigmentation with the use of Thiamidol.

It has shown efficacy in addressing facial hyperpigmentation, post-inflammatory hyperpigmentation, and age spots.

Prevention of Reappearance:

Thiamidol not only addresses existing pigment spots but also prevents their reappearance, contributing to long-term efficacy.

References of Thiamidol 1428450-95-6

Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma

Craig Arrowitz 1, Andrea M. Schoelermann 2, Tobias Mann 2, Lily I. Jiang 3, Teresa Weber 1, Ludger Kolbe 2

Journal of Investigative Dermatology Volume 139, Issue 8, August 2019, Pages 1691-1698.e6

To investigate new treatment options, we performed an exploratory double-blinded, randomized split-face study to assess the efficacy of the tyrosinase inhibitor Thiamidol compared to hydroquinone in women with mild to moderate melasma.

Thiamidol containing treatment regimens in facial hyperpigmentation: An international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study

W. G. Philipp-Dormston, A. Vila Echagüe, S. H. Pérez Damonte, J. Riedel, A. Filbry, K. Warnke, C. Lofrano, D. Roggenkamp, G. Nippel

International Journal of Cosmetic Science, Volume42, Issue4 August 2020 Pages 377-387

To identify the optimal number of daily Thiamidol applications, we conducted a split-face study comparing the efficacy and tolerability of four-times with two-times daily application. Subsequently, we evaluated the efficacy and tolerability of a typical face care regimen containing Thiamidol in a real-world study.